New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
11:58 EDTNKTR, CTXS, RPRX, SPPI, HLFStocks with increasing implied volatility; HLF RPRX NKTR SPPI CTXS
News For HLF;RPRX;NKTR;SPPI;CTXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
06:12 EDTHLFHerbalife requests user information from Twitter, Reuters reports
Herbalife (HLF) has filed a petition seeking information from Twitter (TWTR) to find an anonymous user who posted defamatory tweets against Herbalife, Reuters reports. Herbalife wants Twitter to provide IP addresses as well as account details of the user so that the company can pursue legal action, the report says. Reference Link
July 21, 2015
10:01 EDTHLFOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 20, 2015
16:40 EDTHLFHerbalife initiated with a Neutral at Sterne Agee CRT
Subscribe for More Information
July 16, 2015
15:42 EDTNKTRNektar partner Baxalta releases complete data from Phase II/III BAX 855 study
Nektar Therapeutics (NKTR) reported that partner Baxalta announced the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta's investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, a leading treatment for hemophilia A with more than 11 years of real-world patient experience. Through a collaboration with Nektar, BAX 855 leverages proprietary pegylation technology designed to prolong the amount of factor VIII available for use in the body. As previously disclosed, BAX 855 met the study's primary endpoint for the prevention of bleeding episodes and the treatment with prophylaxis compared to on-demand treatment. Patients in the twice-weekly prophylaxis arm of the trial experienced a 95% reduction in median annualized bleed rate as compared with those in the on-demand arm. BAX 855 was also effective in treating all bleeding episodes, 95.9% of which were controlled with one or two infusions at a median dose of 29.0 IU/kg per infusion.
July 15, 2015
06:03 EDTHLFStocks with implied volatility above IV index mean; P HLF
Subscribe for More Information
July 14, 2015
05:59 EDTHLFStocks with implied volatility above IV index mean; P HLF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use